QUOTE AND NEWS
TheStreet.com  Nov 17  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.  TheStreet Ratings quantitative algorithm...
Forbes  Nov 10  Comment 
Investors eyeing a purchase of Fluidigm Corp (NASD: FLDM) shares, but cautious about paying the going market price of $29.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
SeekingAlpha  Aug 8  Comment 
By Andy Batts: Fluidigm's (NASDAQ:FLDM) total revenue increased 58% year-over-year to $27.6 million in the second quarter of 2014, from $17.5 million in the second quarter of 2013. The company's strong organic business across single-cell genomics...
Forbes  Aug 4  Comment 
Investors eyeing a purchase of Fluidigm Corp (NASD: FLDM) stock, but cautious about paying the going market price of $27.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
SeekingAlpha  Aug 2  Comment 
Fluidigm Corporation (NASDAQ:FLDM) Q2 2014 Earnings Conference Call July 31, 2014 05:00 p.m. ET Executives Un Kwon-Casado – VP, Corporate Development Gajus Worthington – President and CEO Vikram Jog – CFO Analysts Dan...
SeekingAlpha  May 6  Comment 
Fluidigm Corporation (FLDM) Q1 2014 Earnings Conference Call May 5, 2014 5:00 p.m. ET Executives Un Kwon-Casado - VP, Corporate Development Gajus Worthington - President and CEO Vikram Jog - CFO Analysts Dan Leonard -...
DailyFinance  May 5  Comment 
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the first quarter ended March 31, 2014. Total revenue for the first quarter of 2014 was $25.7 million, an increase of 77% from $14.5 million in...




 
TOP CONTRIBUTORS

Fluidigm (NASDAQ:FLDM) makes microfluidic systems which are used in the life sciences and agricultural biotechnology industries. The company's microfluidic systems are instruments such as chips and reagents used in laboratories. These systems decrease costs, increase output, and allow the laboratory to run processes that would normally be infeasible. Fluidigm has increased the number of fluid components on a single chip which allows the laboratory to run complex experiments on a smaller surface area. Fluidigm has sold its products to 200 different customers across 20 different countries.[1]

In addition to cutting cost for its clients, Fluidigm also allows them to run experiments normally not possible. Laboratories can conduct 24 times more gene expression experiments and 36,960 simultaneous reactions on a single fluidic chip.[2] Fluidigm's chips also improve data quality as each individual fluid compartment are highly homogeneous. This allows for different conditions to be tested across a single chip without conditions ranging from compartment to compartment.[3]

The company's initial public offering of stock on the NASDAQ occurred on February 9, 2011. The company offered 5.6M shares each for $13.50. The inital price range was $13.50-$15.50. This brought the deal size to $75M. The company had originally planned to sell 5.2M shares, but increased its offer to 5.6M. The lead underwriter of the deal were Deutsche Bank AG (DB) and Piper Jaffray Companies (PJC).[4]

For the first 9 months of 2010, the company's total revenue was $36M. The company reported a net loss for the same time period of $13.8M. This was largely due to a high Research & Development expense. For the first 9 months of 2010, the company spent $10M on research and development.[5]

References

  1. FLDM S-1/A 2011 PROSPECTUS OVERVIEW "Overview" pg 1
  2. FLDM S-1/A 2011 PROSPECTUS OVERVIEW "Overview" pg 2
  3. FLDM S-1/A 2011 PROSPECTUS OVERVIEW "The Fluidigm Solution" pg 3-4
  4. Renaissance Capital - IPO Home "Fluidigm prices upsized IPO at $13.50, the low end of the range" 10 Feb 2011
  5. FLDM S-1/A 2011 PROSPECTUS OVERVIEW "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 9
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki